PBYI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Puma Biotechnology Inc (PBYI) is not an ideal buy for a beginner, long-term investor at this moment. While the company has shown strong revenue growth in its latest quarter, the significant insider and hedge fund selling, declining net income, and lack of strong proprietary trading signals suggest caution. Additionally, the RSI indicates overbought conditions, and there are no significant positive catalysts to outweigh the risks.
The MACD is positive and expanding, indicating bullish momentum. The RSI is at 78.51, suggesting overbought conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 7.53 and 7.813, while support levels are at 6.613 and 6.33. The stock is currently trading near resistance, which may limit upside potential.
The company reported a 27.7% YoY revenue increase in Q4 2025, beating expectations. Revenue guidance for 2026 is strong, with projections between $194 million and $198 million. Clinical trial enrollment is progressing faster than expected.
Insiders and hedge funds are selling heavily, with insider selling up 230.93% and hedge fund selling up 203.10%. Net income and EPS have declined YoY (-30.39% and -33.33%, respectively). Gross margin has also dropped by 9.28%. The RSI indicates overbought conditions, and there is no recent congress trading data or strong proprietary trading signals.
In Q4 2025, revenue increased by 27.72% YoY to $75.5 million, driven by strong royalty revenue. However, net income dropped by 30.39% YoY to $13.44 million, and EPS declined by 33.33% YoY to $0.26. Gross margin decreased to 69.35%, down 9.28% YoY.
No recent analyst rating or price target changes are available for analysis.
